Dyne Therapeutics - DYN Operating profit EBITDA

The resilience of Dyne Therapeutics, Inc. (DYN) is based on access to global investments and patent protection. The EBITDA trend on the GURU.Markets chart confirms this stability, where 0.00 captures the current state of the parameter. Revenue growth relies on the development of muscular dystrophy therapies, while financial reliability is supported by liquidity and the control of costs associated with oligonucleotide clinical trials.

DYN - Dyne Therapeutics Profit before payment of interest, taxes and amortization over the range 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for Dyne Therapeutics (DYN)

- market value and analyst target forecast:

Market Price Dyne Corp|DYN - Consensus Target

- issuer market value details:

Market Capitalization Dyne Therapeutics|DYN - Total Company Value

- book value of equity indicators:

Accounting Value of a Share Dyne Therapeutics|DYN - Company Book Value|Market-to-Book Ratio dyne-tx.com|DYN - Aggregate Company Assets

- debt level and financial liquidity data:

- earnings and market ratios statistics:

DYN - Net Income|Expected Net Profit Dyne Therapeutics, Inc.|DYN - Price to Earnings Ratio|Price to Future Earnings Ratio dyne-tx.com|DYN - PEG Multiple|Company Value to EBITDA Dyne Therapeutics|DYN - Operating profit before deduction of amortization|Earnings per share for the trailing year Dyne Therapeutics|DYN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months dyne-tx.com|DYN - Earnings growth in current year|Expected earnings per share trend next year Dyne Therapeutics, Inc.

Summary company analytics:DYN, Dyne Corp

Manufactured products of Dyne Therapeutics, Inc.

This indicator measures real cash flow from core operations, adjusted for non-cash charges and fiscal burdens, allowing for an assessment of the business's internal efficiency. An analysis of EBITDA reflects the ability of Dyne Therapeutics, Inc. (DYN) to fund the development of innovative RNA platforms for the treatment of myopathies, leveraging its high reputation within the scientific community.

Competitor analysis for Dyne Therapeutics, Inc.

Jazz Pharmaceuticals Corp (JAZZ) - Profit before interest, taxes and amortization|CYTK: Operating profit before deduction of amortization|PTCT - Operating profit EBITDA|Scholar Rock Holding Corporation (SRRK) - Profit before payment of interest, taxes and amortization|Centessa Pharmaceuticals plc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Edgewise Pharma|Profit before interest, taxes and amortization Rapport Corp RAPP|Profit before payment of interest, taxes and amortization Alumis Inc. (ALMS)|Profit before payment of interest, taxes and amortization ZVRA (zevra.com)|Profit before payment of interest, taxes and amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc (LRMR) - Profit before interest, taxes and amortization|Capricor - Operating profit EBITDA|Operating profit before depreciation charges Entrada Therapeutics, Inc (TRDA)|PTHS (Channel Therapeutics) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization MediciNova (MNOV)|SER (Serina Therapeutics) - Operating profit EBITDA|Operating profit before amortization BTAI (BioXcel Therapeutics Inc)|Operating profit before deduction of amortization PMN (ProMIS Neurosciences)|APUS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization AEON Biopharma, Inc. AEON|NLSP: Operating profit before amortization|Bionomics Ltd - Operating profit EBITDA|Profit before interest, taxes and amortization fsdpharma.com|RETA (Reata) - Operating profit before deduction of amortization